Reported 18 days ago
Nabla Bio, a U.S. biotech firm, has announced a significant expansion of its partnership with Japan's Takeda Pharmaceutical to enhance artificial intelligence in drug discovery. The new multi-year agreement, building on a previous collaboration from 2022, includes substantial financial commitments and is aimed at developing protein-based therapeutics for complex diseases. This partnership highlights the pharmaceutical industry's increasing reliance on AI to streamline drug development processes.
Source: YAHOO